|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.00 EUR | -4.26% |
|
+3.30% | -5.84% |
| 04-22 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 04-05 | Boiron SA announces Annual dividend, payable on June 05, 2026 | CI |
| Market Cap | 490M 559M 452M 422M 795M 52.87B 813M 5.44B 2.1B 26.08B 2.1B 2.05B 90.55B | P/E 2024 |
41x | P/E 2025 | 16.1x |
|---|---|---|---|---|---|
| Enterprise Value | 442M 505M 408M 381M 717M 47.7B 733M 4.91B 1.89B 23.53B 1.89B 1.85B 81.7B | EV / Sales 2024 |
0.85x | EV / Sales 2025 | 0.95x |
| Free-Float |
19.96% | Yield 2024 |
4.48% | Yield 2025 | 4.46% |
| 1 week | +3.30% | ||
| Current month | +0.71% | ||
| 1 month | +2.92% | ||
| 3 months | +11.90% | ||
| 6 months | -6.00% | ||
| Current year | -5.84% |
| 1 week | 26.8 | 28.5 | |
| 1 month | 26.5 | 29 | |
| 3 years | 20.7 | 55.3 | |
| 5 years | 20.7 | 55.3 | |
| 10 years | 20.7 | 92.03 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Houdayer
CEO | Chief Executive Officer | 56 | 2024-12-31 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
Isabelle Chanel
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Thierry Boiron
CHM | Chairman | 65 | 2011-06-30 |
| Director/Board Member | 54 | 2010-03-09 | |
| Director/Board Member | 51 | 2013-05-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.26% | +3.30% | +28.18% | -26.56% | 558M | ||
| +3.26% | +0.21% | -13.15% | -6.35% | 12.33B | ||
| +5.18% | +0.21% | -35.64% | -57.79% | 4.51B | ||
| +5.34% | +0.26% | -12.86% | -6.22% | 4.11B | ||
| +6.00% | +3.46% | +10.84% | -38.89% | 3.6B | ||
| +6.96% | +0.34% | +13.92% | -15.00% | 3.58B | ||
| +3.90% | +1.85% | -8.91% | -7.63% | 3.44B | ||
| +3.32% | -2.91% | -12.76% | -2.91% | 2.91B | ||
| +5.85% | -0.46% | -5.88% | -24.18% | 2.23B | ||
| +2.79% | -1.04% | -12.25% | +25.46% | 1.6B | ||
| Average | +4.73% | +0.07% | -4.85% | -16.01% | 4.26B | |
| Weighted average by Cap. | +4.51% | +0.13% | -9.57% | -15.98% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 488M 557M 450M 420M 791M 52.65B 809M 5.42B 2.09B 25.97B 2.09B 2.05B 90.17B | 501M 572M 463M 432M 813M 54.11B 832M 5.57B 2.15B 26.69B 2.15B 2.1B 92.68B |
| Net income | 11.34M 12.95M 10.47M 9.77M 18.4M 1.22B 18.82M 126M 48.62M 604M 48.62M 47.55M 2.1B | 32.64M 37.28M 30.14M 28.14M 52.97M 3.52B 54.18M 363M 140M 1.74B 140M 137M 6.04B |
| Net Debt | -49.74M -56.8M -45.92M -42.88M -80.72M -5.37B -82.55M -553M -213M -2.65B -213M -209M -9.2B | -47.86M -54.65M -44.18M -41.25M -77.66M -5.17B -79.43M -532M -205M -2.55B -205M -201M -8.85B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 26-06-29 | €27.00 | -4.26% |
| 26-06-26 | €28.20 | +2.17% |
| 26-06-25 | €27.60 | +0.73% |
| 26-06-24 | €27.40 | -1.79% |
| 26-06-23 | €27.90 | +1.82% |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BOI Stock
- BON Stock
Select your edition
All financial news and data tailored to specific country editions
















